Date Title Document
Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence Date 12/28/15 Title Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence Download PDF
Valeant Provides Financial Guidance Update Date 12/16/15 Title Valeant Provides Financial Guidance Update Download PDF
Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies Date 12/15/15 Title Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies Download PDF
Valeant To Hold Investor Day On December 16 (Updated) Date 11/20/15 Title Valeant To Hold Investor Day On December 16 (Updated) Download PDF
Valeant Pharmaceuticals To Present At Industry Conference Date 11/12/15 Title Valeant Pharmaceuticals To Present At Industry Conference Download PDF
Valeant To Hold Conference Call For Investors To Provide Business Update Date 11/09/15 Title Valeant To Hold Conference Call For Investors To Provide Business Update Download PDF
Valeant Issues Statement On Sales Of Company Stock Date 11/06/15 Title Valeant Issues Statement On Sales Of Company Stock Download PDF
Valeant To Terminate Relationship With Philidor Date 10/30/15 Title Valeant To Terminate Relationship With Philidor Download PDF
Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee Date 10/30/15 Title Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee Download PDF
Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors Date 10/26/15 Title Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors Download PDF
Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor Date 10/26/15 Title Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor Download PDF
Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals Date 10/26/15 Title Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals Download PDF
Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015 Date 10/22/15 Title Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015 Download PDF
Valeant Pharmaceuticals Responds To Erroneous Report Date 10/21/15 Title Valeant Pharmaceuticals Responds To Erroneous Report Download PDF
Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results Date 10/19/15 Title Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Date 10/15/15 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc. Date 10/15/15 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc. Download PDF
Valeant Provides Update Regarding Government Inquiries Date 10/14/15 Title Valeant Provides Update Regarding Government Inquiries Download PDF
Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant Date 10/13/15 Title Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc. Date 10/05/15 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc. Download PDF
Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015 Date 10/05/15 Title Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015 Download PDF
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod) Date 09/22/15 Title Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod) Download PDF
Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR® Date 09/08/15 Title Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR® Download PDF
Valeant Pharmaceuticals To Acquire Synergetics USA Date 09/02/15 Title Valeant Pharmaceuticals To Acquire Synergetics USA Download PDF
Valeant And AstraZeneca To Partner On Brodalumab Date 09/01/15 Title Valeant And AstraZeneca To Partner On Brodalumab Download PDF
Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors Date 08/25/15 Title Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors Download PDF
Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals Date 08/20/15 Title Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results Date 07/23/15 Title Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results Download PDF
Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical Date 07/17/15 Title Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical Download PDF
Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 Date 06/24/15 Title Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 Download PDF
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Date 06/23/15 Title Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Download PDF
Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer Date 06/11/15 Title Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer Download PDF
Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) Date 05/27/15 Title Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) Download PDF
Valeant Pharmaceuticals Announces 2015 Annual Meeting Results Date 05/19/15 Title Valeant Pharmaceuticals Announces 2015 Annual Meeting Results Download PDF
Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders Date 05/12/15 Title Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results Date 04/29/15 Title Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results Download PDF
Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version) Date 04/29/15 Title Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version) Download PDF
Valeant Announces CFO Succession Plan And Additional Executive Appointment Date 04/29/15 Title Valeant Announces CFO Succession Plan And Additional Executive Appointment Download PDF
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain Date 04/24/15 Title RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain Download PDF
Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015 Date 04/09/15 Title Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015 Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Date 04/01/15 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Date 04/01/15 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Download PDF
Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Date 04/01/15 Title Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Download PDF
Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 Date 04/01/15 Title Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 Download PDF
Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 Date 04/01/15 Title Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 Download PDF
Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares Date 03/27/15 Title Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares Date 03/17/15 Title Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant And Salix Agree On Amended Terms To Merger Agreement Date 03/16/15 Title Valeant And Salix Agree On Amended Terms To Merger Agreement Download PDF
Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares Date 03/16/15 Title Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant Announces HSR Clearance For Salix Acquisition Date 03/13/15 Title Valeant Announces HSR Clearance For Salix Acquisition Download PDF
Valeant Announces Pricing Of Private Offering Of Senior Notes Date 03/13/15 Title Valeant Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Comments On Endo Offer To Acquire Salix Date 03/11/15 Title Valeant Comments On Endo Offer To Acquire Salix Download PDF
Valeant Announces Launch Of Private Offering Of Senior Notes Date 03/09/15 Title Valeant Announces Launch Of Private Offering Of Senior Notes Download PDF
PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer Date 02/25/15 Title PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer Download PDF
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results Date 02/22/15 Title Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results Download PDF
Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash Date 02/22/15 Title Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash Download PDF
Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon Date 02/10/15 Title Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon Download PDF
Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015 Date 02/05/15 Title Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015 Download PDF
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Date 02/05/15 Title Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Download PDF
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Date 01/29/15 Title Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Download PDF
Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform Date 01/20/15 Title Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform Download PDF
Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Date 01/15/15 Title Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Download PDF
Valeant Announces Launch of Private Offering of Senior Notes Date 01/15/15 Title Valeant Announces Launch of Private Offering of Senior Notes Download PDF
Valeant Announces Pricing Of Private Offering Of Senior Notes Date 01/15/15 Title Valeant Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference Date 01/06/15 Title Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference Download PDF
Annual Report

2015 Annual Report

The right products
The right philosophy.
record organic growth.

View All